Question 400 — pharmacy and medications

Summary

Mr. Olivier Dussopt draws the attention of the Minister of Solidarity and Health to the non-inscription on the so-called “additional” list of certain innovative medications used in the treatment of multiple myeloma. The latter is a malignant disease of the bone marrow that affects nearly 5,000 new people each year. Today, the number of people suffering from multiple myeloma is estimated at 30,000 people in France. In In terms of treatment, a major breakthrough was obtained in 2015 with the delivery of marketing authorization for five new drugs at the initiative of the European Medicines Agency. However, some of these innovative medicines, which meet all the conditions to be included on the “additional list”, such as carfilzomib, do not benefit from the exceptional financing system allowing hospitals to offer these innovative and expensive treatments to patients as quickly as possible by having their financing directly covered by health insurance. Also, he would like to know the reasons for these non-registrations and if the Government plans to put an end to them.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.